Clinical Policy: Zuranolone (Zurzuvae)
Defines medical necessity criteria, prescriber requirements, dosing limits, approval duration, and exclusions for Zurzuvae (zuranolone) for treatment of postpartum depression across Centene lines of business (Commercial, HIM, Medicaid).
Added obstetrician-gynecologist as an additional prescriber specialty and specialist that can perform a clinical interview to confirm severe depression; added BDI and EPDS scales as additional methods to identify severe depression.
Updated dosing regimens and removed commercially unavailable branded therapeutic alternatives in Appendix B per Clinical Pharmacology; references reviewed and updated.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.